[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subclinical-atherosclerotic-cardiovascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subclinical-atherosclerotic-cardiovascular-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100633257","phase-3-aspirin-in-subclinical-coronary-artery-disease-a-pilot-randomised-controlled-trial-100633257",false,"NCT07524335","Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial","ASCAD-P","Inclusion Criteria:\n\n1. Documented coronary atherosclerosis, as defined by one of the following criteria:\n\n   1. Coronary artery calcium (CAC) score \\> 0;\n   2. Cardiac CT angiography (CCTA) \u002F CoroScan: lesions \\\u003C70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \\\u003C50% in the left main coronary artery;\n   3. Coronary angiography: lesions \\\u003C70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \\\u003C50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease.\n2. Willing and able to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n1. History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure;\n2. Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication;\n3. Clear contraindication to aspirin;\n4. History of significant bleeding within the past year;\n5. Severe illness with limited life expectancy (i.e., \\\u003C5 years);\n6. Any condition that, in the investigator's judgment, would make participation unsafe for the patient.","ALL","40 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.",[26,27],"Coronary Artery Disease","Subclinical Atherosclerotic Cardiovascular Disease",[29,30,31,32,33,34,35,36,37,38,39],"Pilot Study","Feasability Study","Randomized","Clinical Trial","Prospective","Pragmatic Trial","Aspirin","Coronary artery disease","Bleeding","Major Adverse Cardiovascular Events","Antiplatelet","NOT_YET_RECRUITING","2026-05-07",{"date":43,"type":44},"2026-05-12","ACTUAL",{"date":46,"type":20},"2026-05-01",{"date":48,"type":20},"2028-05-01",{"name":50,"class":51},"Montreal Heart Institute","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":16,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":66,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":78,"leadSponsor":80,"locationsCount":52},"100632973","mistic-study-atherosclerosis-neurocognition--cardiovascular-signaling-100632973","NCT07520643","MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling","Multilevel and Interdisciplinary Assessment of Subclinical to Clinical Atherosclerosis Interactions With Neurocognitive Function and Cardiovascular System Through Endothelial and Inflammatory Cell Signalling: The MISTIC Study","MISTIC","Control Group\n\nInclusion Criteria:\n\n* Age \\>= 18 years\n* Capacity to provide informed consent\n* Documented coronary artery stenosis ≥ 50 % through peripheral vascular ultrasound imaging.Documented coronary artery stenosis ≥ 50 % through peripheral vascular ultrasound imaging.\n\nExclusion Criteria:\n\n* Prior ischemic cardiac events (e.g., myocardial infarction, unstable angina).\n* Major electrophysiological disorders.\n* History of stroke or transient ischemic attack.\n* Ongoing renal replacement therapy (dialysis).\n* Use of systemic immunosuppressive or anti-inflammatory medications (beyond low-dose aspirin).\n* Any chronic inflammatory or autoimmune disease.\n* Active infectious disease at the time of enrolment.\n* Active malignancy or cancer treatment within the past 5 years.\n\nCoronary Artery Disease Group\n\nInclusion Criteria:\n\n* Age \\>= 18 years\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Prior ischemic cardiac events (e.g., myocardial infarction, unstable angina).\n* Major electrophysiological disorders.\n* History of stroke or transient ischemic attack.\n* Ongoing renal replacement therapy (dialysis).\n* Use of systemic immunosuppressive or anti-inflammatory medications (beyond low-dose aspirin).\n* Any chronic inflammatory or autoimmune disease.\n* Active infectious disease at the time of enrolment.\n* Active malignancy or cancer treatment within the past 5 years.",true,"18 Years","80 Years",{"count":65,"type":20},1000,"6 Months","OBSERVATIONAL","The MISTIC study is a non-profit, cross-sectional clinical research project aimed at investigating the relationship between atherosclerosis and both cardiovascular and cognitive function in adult populations.\n\nAtherosclerosis is a progressive condition characterized by the accumulation of material within arterial walls, leading to vascular narrowing and impaired blood flow. While its most recognized consequences are acute events such as myocardial infarction or stroke, earlier stages of the disease, often asymptomatic, may already be associated with functional changes affecting multiple organ systems.\n\nThis study focuses on evaluating the association between vascular health and cognitive performance at a single time point. Atherosclerotic burden will be assessed using non-invasive imaging techniques, including carotid intima-media thickness and coronary calcium scoring. Cognitive performance will be measured using standardized neuropsychological tests.\n\nApproximately 1000 participants will be enrolled and divided into two groups: a control group without clinically established cardiovascular disease, and a group of patients with coronary artery disease (CAD). All participants will undergo clinical evaluation, vascular imaging, cognitive testing, and analysis of biological samples.\n\nThe primary objective is to determine whether increasing atherosclerotic burden is associated with measurable differences in cognitive and cardiovascular function. Secondary aims include identifying patterns that may help improve early detection and risk stratification of vascular disease.\n\nThe results of this study are expected to contribute to a better understanding of atherosclerosis as a systemic condition and to support the development of preventive strategies targeting early stages of vascular disease.",[27,70],"Neurocognitive Decline",[72,70,73],"Atherosclerosis","Inflammation","2026-04-02",{"date":76,"type":44},"2026-04-09",{"date":46,"type":20},{"date":79,"type":20},"2030-04-30",{"name":81,"class":51},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]